Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National prospective study of immune checkpoint inhibitor-induced hepatitis with prednisolone versus mycophenolate mofetil at relapse
2020-004483-26Phase 2Terminated
- Sponsor
- National Center for Cancer Immune Therapy
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Drug-induced hepatitis (DILI) and hepatitis comparing Prednisolone at relapse with Mycophenolate mofetil at relapse (2 arms). Primary endpoints: Treatment efficacy by liver biochemistry improvement and Time to oral prednisolone and discharge. Started Sep 2020; status: terminated.
02
Drugs
prednisolonemycophenolate mofetil
03
Conditions
Drug-induced hepatitis (DILI)hepatitis
Beyond the preview
Go deeper on 2020-004483-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004483-26.